NeuroPace (NPCE) Q1 2026 Earnings Transcript

NeuroPace reported Q1 revenue of $22.1 million, or $22.0 million excluding DIXI Medical, up 8% year over year, with RNS system revenue rising 19.5% to $21.7 million. The company raised 2026 revenue guidance to $99 million-$101 million from $98 million-$100 million and improved adjusted EBITDA loss guidance to $8.5 million-$9.5 million, while also highlighting strong pipeline metrics, a 77% median seizure reduction in NAUTILUS 18-month data, and continued progress on its AI product suite. FDA review of the IGE PMA supplement remains ongoing after a clock pause, but management said a midyear determination is still expected.

Analysis

The key incremental signal is not the modest beat; it is the shape of the demand curve. NPCE is showing that utilization is no longer just a narrow-center adoption story — referral leakage from community settings plus higher funnel velocity suggests the business is becoming less dependent on a handful of flagship epilepsy centers. That is important because it can de-risk quarter-to-quarter volatility and make the revenue base more durable, even before any IGE expansion hits.

The underappreciated second-order effect is reimbursement optionality on the replacement cycle. Management is effectively telling us that replacements are still immaterial today, but the reimbursement stack is moving in the right direction just as the installed base ages into a multi-year upgrade cycle. If replacements become a larger share over the next 12-24 months, NPCE should see a mix shift toward higher repeatability and lower commercial acquisition cost per dollar of revenue, which is how this starts to look more like a durable platform rather than a one-time device sell.

The biggest near-term catalyst remains the FDA decision on the IGE supplement, but the market may be underestimating how messy commercialization could be even after approval. Coverage expansion across payers will likely lag the label, so the real earnings inflection is probably months after approval, not days. That creates a setup where the stock can rerate on approval but still be vulnerable to disappointment if investors price in too much second-half revenue too early.

The contrarian read is that AI is not just a narrative add-on here; it is the most credible path to widening the moat and improving physician workflow, which could lift adoption more than the market models. However, the AI suite is still pre-monetization and could easily be overvalued in the equity if investors assume immediate contribution. The cleaner trade is to own the operational leverage now and wait for either approval-driven upside or a pullback if reimbursement timelines extend.

Key Decisions for Investors

• Long NPCE into the midyear FDA decision window (1-3 months) with a target of rerating on approval; risk is limited upside if the market has already discounted a positive outcome, but the downside is larger if the clock pause signals more substantive scrutiny.
• Buy NPCE on any post-approval pullback rather than front-running the announcement; the better entry may come once the market realizes reimbursement will likely ramp over 6-12 months instead of immediately.
• Pair trade: long NPCE / short a slower-growth medtech name with lower operating leverage over the next 6-12 months; NPCE has the cleaner top-line inflection and a more visible path to margin expansion if funnel metrics hold.
• If holding NPCE, sell upside calls against the position into binary regulatory events to monetize elevated implied volatility; use a 1-2 month tenor to capture event premium while capping some upside.
• Do not chase the stock solely on AI headlines; treat the AI suite as a longer-dated option and size exposure accordingly until there is evidence of meaningful workflow monetization.